L
LumiThera
Medical device company focused on led and laser treatments for acute and chronic ocular disease
About LumiThera
LumiThera is a pioneering medical device company specializing in the development of photobiomodulation (PBM) treatments for ocular diseases, primarily targeting age-related macular degeneration (AMD). The company operates in the healthcare and medical technology market, focusing on providing innovative solutions to improve vision and quality of life for patients. LumiThera's flagship product, the Valeda Light Delivery System, is the first approved treatment for dry AMD using PBM. This system employs a multi-wavelength approach to stimulate cellular function, enhancing energy production within the mitochondria and leading to improved visual outcomes.
LumiThera serves a diverse client base, including ophthalmologists, optometrists, and healthcare professionals specializing in ocular health. The company's business model revolves around the sale and distribution of the Valeda Light Delivery System, as well as ongoing research and development to expand its product offerings. Revenue is generated through direct sales, partnerships with healthcare providers, and potential licensing agreements.
LumiThera's market presence is bolstered by its commitment to clinical research and its focus on addressing unmet medical needs in the field of ophthalmology. The company aims to establish itself as a leader in PBM treatments, leveraging its innovative technology to provide effective and non-invasive solutions for degenerative eye diseases.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2013
- Headquarters
- Poulsbo, United States
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 58.5/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Non-Invasive medical devices and treatments, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 2 companies, latest Jul 2022
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Sep 2025 | $0 | — | Alcon | ↗ |
| DEBTDebt | Mar 2022 | $5.5M | — | Serengeti Asset Management | — |
Growth signals
Latest recorded traffic for LumiThera is 80 monthly website visits, down 97.7% over the last three months. LumiThera's team declined 36% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
DiopsysMontville, United StatesMedical devices company offering erg and vep vision testing solutions
→
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Keiretsu Forum Northwest
Keiretsu Capital- WCWaterStone Capital
Series B and later6 investors entered at this stage
WaterStar Capital
Nikon
Mercury Fund
Celeste Management
Imagine Ventures
Serengeti Asset Management
Other known investors4 additional known investors
Alcon
University of Wisconsin-Milwaukee
Keiretsu Forum
Small Business Innovation Research
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about LumiThera on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See LumiThera’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.